Comparing orelabrutinib and lenalidomide with rituximab for MZL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests two different drug combinations for people with marginal zone lymphoma that has come back or stopped responding to previous treatment. One group gets orelabrutinib plus rituximab, and the other gets lenalidomide plus rituximab, to see which works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have marginal zone lymphoma (a type of B-cell non-Hodgkin lymphoma) confirmed by biopsy.
- You have already received at least one treatment that includes rituximab (an anti-CD20 antibody) before.
- Your lymphoma has come back or did not respond well to your last treatment.
- You have at least one tumor that can be seen on a CT or MRI scan.
- You are able to be up and about with light activity (ECOG 0-2).
- You have not taken a BTK inhibitor (like ibrutinib) in the past.
- You have not been treated with lenalidomide plus rituximab before without success.
- Your lymphoma has not spread to your brain or spinal fluid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
This trial tests a combination of two targeted drugs (orelabrutinib and obinutuzumab) as a first treatment for marginal zone lymphoma that has returned or progressed after local therapy. The goal is to see if this combination works better than current options.
This trial tests a combination of three drugs (orelabrutinib, zebetuzumab, and lenalidomide) for people newly diagnosed with a type of lymphoma called marginal zone lymphoma (MZL). If you qualify, you may receive this treatment to help control the disease.
This study compares two oral targeted therapies (ICP-248 plus orelabrutinib vs. pirtobrutinib) for people with mantle cell lymphoma that has returned or stopped responding to treatment. It aims to see which combination works better.
This trial tests a new combination of two drugs (orelabrutinib and rituximab) compared to the standard R-CVP chemotherapy for people with newly diagnosed marginal zone lymphoma. The goal is to see which approach works better and has fewer side effects.
This trial tests a combination of two targeted therapies—oralebrutinib (a pill that blocks a protein in cancer cells) and rituximab (an antibody infusion)—for people with marginal zone lymphoma that has returned or cannot be treated with local therapies. The goal is to see if this combo works well and is safe.
Hear when a new Relapsed/Refractory Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.